Inadequate pancreatic enzyme supply to the small intestine is a defining feature of exocrine pancreatic insufficiency (EPI). Malabsorption due to insufficient pancreatic enzyme supply to the small intestine is a hallmark of exocrine pancreatic insufficiency (EPI). Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market clinical signs frequently lack specificity, which might delay timely discovery and diagnosis. The lack of extremely accurate or specific testing, which causes incorrect diagnoses and inadequate treatments, lies at the heart of this clinical conundrum. The diagnosis of EPI relies heavily on the identification of high-risk individuals, which includes those who have pancreatic parenchyma disorders such chronic pancreatitis, pancreatic cancer, cystic fibrosis, and those who have had their pancreas removed for benign and malignant disease. The number of additional conditions that may also result in EPI is less well known.
Read More @ https://cmiinfonest.blogspot.com/2023/03/exocrine-pancreatic-insufficiency-epi.html
